Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 8, 2026, details material definitive agreements entered into by Jaguar Health, Inc. (JAGX) on June 9, 2026. The filing follows the reconvened 2026 Annual Meeting of Stockholders held on June 8, 2026, where the Company obtained necessary stockholder approvals for the transactions described below.
Key Financial Metrics and Capital Structure
- Equity Line of Credit (ELOC): The Company entered into an agreement with an accredited Institutional Investor to purchase up to $40 million of Common Stock.
- Preferred Stock Financing: The Company closed a private placement of 240 shares of Series P Non-Convertible Preferred Stock for an aggregate purchase price of $2 million.
- Commitment Shares: The Company agreed to issue $800,000 worth of Common Stock to the Institutional Investor as consideration for the ELOC Agreement.
- Preferred Stock Terms: Series P Preferred Stock has a stated value of $10,000 per share and accrues dividends at a rate of 8% per year.
- Financial Statements: This filing does not provide revenue, profit, cash flow, or margin data. It focuses exclusively on capital raising activities.
Material Changes and Transaction Details
The Company secured two distinct financing mechanisms to raise capital for general corporate purposes:
- ELOC Structure:
- Purchase Types: Includes Fixed Purchases (max $1.5 million per transaction), VWAP Purchases, and Additional VWAP Purchases (aggregate cap of $4.5 million per date).
- Pricing Floor: Purchases are subject to a floor price of $1.10 per share (the "ELOC Floor Price").
- Ownership Limit: Subject to a 4.99% beneficial ownership limitation for the Institutional Investor.
- Termination: The agreement terminates automatically upon expiration of the registration statement, full funding, delisting, or bankruptcy events.
- Series P Preferred Stock Structure:
- Dividends: Payable quarterly in arrears, either in cash or Common Stock (at Company election), subject to a floor price of $0.546 or the Minimum Price.
- Liquidation Preference: Holders are entitled to the Stated Value plus accrued dividends before any distribution to Common Stockholders.
- Redemption:
- Mandatory: Triggered within two trading days of ELOC proceeds receipt; Company must redeem at least 10% of proceeds.
- Optional: Company may redeem at any time after issuance.
- Forced: Holders may force redemption upon "Triggering Events" (e.g., failure to file registration statements, suspension of trading, missed dividends, or expiration of the third anniversary).
- Conversion: The Series P Preferred Stock is non-convertible.
Guidance, Risks, and Contingencies
- Registration Obligations: The Company must file Form S-1 registration statements for both the ELOC and Preferred Stock securities within 30 days of execution and maintain their effectiveness.
- Ownership Caps: Issuance of shares upon redemption or dividend payment is restricted if it causes a holder to exceed 4.99% beneficial ownership (unless consented to increase to 9.99%).
- Liquidity Risk: There is no established trading market for the Series P Preferred Stock, limiting its liquidity.
- Triggering Events: Failure to maintain registration statements, suspension of trading, or missed dividend payments could trigger forced redemption of the Preferred Stock, potentially causing significant dilution or cash outflow.
Key Facts for Investor Verification
- Verify the effectiveness of the ELOC and Preferred Stock Registration Statements (Form S-1) within the required 30-day window.
- Monitor the Company's Common Stock price relative to the ELOC Floor Price ($1.10) and the Preferred Stock Dividend Floor Price ($0.546).
- Track the timing of the first dividend payment for Series P Preferred Stock and whether it is paid in cash or stock.
- Assess the impact of the 4.99% beneficial ownership limitation on the Company's ability to utilize the ELOC or redeem Preferred Stock.
- Review the Company's cash position to determine if it can meet potential mandatory redemption obligations tied to ELOC proceeds.